After A Tough 2012, Lundbeck Says It Is Benefiting From A Portfolio Revamp
This article was originally published in The Pink Sheet Daily
Following a tough 2012 that saw the end of exclusivity for key drug Lexapro and infrastructure cutbacks in Europe due to pricing headwinds, mid-sized EU specialty pharma Lundbeck could see a return to growth in 2013. The company is banking on regulatory approval of three drugs, and preparing to release first-time Phase III data from a fourth.
You may also be interested in...
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?
Pharma companies are building long-term value propositions that should appeal to Accountable Care Organizations into some go-to-market strategies for new drugs and to repositioning efforts of already marketed drugs that have hit snags. The rationale might seem straightforward—for example, more convenient dosing that improves compliance and cuts down hospitalization rates--but the nuances can be complex. Moreover, even when their products appear to have compelling cases for value, companies have not by and large made ACOs a distinct target for their commercial operations.
While cancer experts are almost giddy with enthusiasm about rapid advances in cancer immunotherapy—in a field not known for euphoria--they are equally pessimistic about market access hurdles as impediments to improved patient care and are seeking manageable approaches to assessing value.